Hyderabad
040-67313131
Secunderabad
040-69097676
Visakhapatnam
0891-6763333
Siliguri
0353-3501000
Chennai
044-69656767
Asian Institute of Nephrology and Urology, Hyderabad cordially invites all Urologists, especially urology residents for conference on "Management Dilemmas in Uro-Oncology"
Date: 23rd February, 2020
Time: 9:00 AM to 5:00 PM
Dr. Makarand Kochikar
Consultant Uro Oncologist
Dr. Srivatsa N
Consultant Uro Oncologist
Session 1Renal cell Carcinoma
| Time | Event | Doctor |
|---|---|---|
| 09.30-10.00 |
Partial Nephrectomy for T2 disease
- Imperative indications - Permissible margin of clearance and ischemia time - Oncological and functional out come |
Dr. Syed Md Ghouse |
| 10.00-10.30 |
Role of peri-operative Targeted therapy
- Neoadjuvant therapy in locally advanced disease - Adjuvant therapy in high risk for recurrence disease - Current evidence and future |
Dr. Makarand Kochikar |
| 10.30-11.00 |
Current status of Cytoreductive Nephrtectomy (CN)
- Individualized management approach to metastatic RCC - Who benefits the most from Cytoreductive Nephrectomy? - Will CN further shrink or synergistic with the advent of immunotherapy? - Current evidence on CN |
Dr. Makarand Kochikar |
| 11.00-11.15 | Tea Break |
Session 2Bladder and Upper tract urothelial malignancy
| Time | Event | Doctor |
|---|---|---|
| 11.15-11.45 |
Restaging TURBT in high risk Non Muscle Invasive Bladder Cancer (NMIBC)?
- Clinical rationale and safety of restaging TURBT - When it can be avoided? - Does MRI Bladder with VI-RADS avoid unnecessary restaging of TURBT? |
Dr. Rajesh Reddy |
| 11.45-12.15 |
Neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC)
- Is it Mandatory? Available evidence? - Is it a overkill in T2 disease - Proposed risk of upstaging in T3 MIBC nonresponders and its implications |
Dr. Srivatsa |
| 12.15-12.45 |
Controversies in the management of upper tract urothelial carcinoma
- Is tissue biopsy or cytology mandatory before the extirpative surgery? - Oncological outcomes and selection of patients for kidney sparing surgery? - Current role of upper urinary tract instillation of topical agents - Current evidence on peri-operative chemotherapy |
Dr. Makarand Kochikar |
| 12.45-13.30 | Lunch Break |
Session 3Carcinoma Prostate
| Time | Event | Doctor |
|---|---|---|
| 13.30-14.00 |
Prebiopsy multiparametric MRI
- Is prebiopsy mpMRI mandatory for all patients with suspected prostate Cancer based on elevated PSA? - Added value of MRI targeted biopsy and its applicability in Indian scenario |
Dr. Srivatsa |
| 14.00-14.30 |
Localized and Locally advanced carcinoma prostate
- Management options and key factors to select optimal treatment modality - Rationale and extent of lymph node dissection in intermediate risk localized disease |
Dr. Makarand Kochikar |
| 14.30-15.00 |
Biochemical Failure after radical prostatectomy
- Risk factors of relapse after radical prostatectomy and their impact on further management - Current evidence on adjuvant vs salvage radiotherapy after radical prostatectomy - Management of PSA only recurrence and PSA persistence after Radical prostatectomy |
Dr. Makarand Kochikar |
| 15.00-15.15 | Tea Break | |
| 15.15-15.45 |
Metastatic carcinoma prostate
- Definition and management of oligometastatic disease - Changing treatment paradigm of metastatic Castrate sensitive prostate carcinoma and current evidence |
Dr. Srivatsa |
| 15-45-16.15 |
Non-metastatic Castrate resistant prostate carcinoma
- Definition and clinical scenarios - Evolving landscape in the management of nm-CRPC |
Dr. Rajesh Reddy |
| 16.15-16.45 |
Optimizing bone health in carcinoma prostate - when and what to start?
- Bone health assessment - Options to improvise bone health |
Dr. Srivatsa |
| 17.00-19.00 |
Live operative workshop
Dinner follows |
- |
